Researcher Profile

Researcher Profile

Patricia McLaughlin, MS, DEd

Patricia McLaughlin, MS, DEd

Professor, Department of Neural and Behavioral Sciences
Scientific Program:Experimental Therapeutics
pxm9@psu.edu

Research Interests

Dr. Patricia McLaughlin’s research focuses on the Opioid Growth Factor (OGF) – OGF receptor (OGFr) pathway and mechanisms of action in homeostasis and disease. Early collaborative work with Dr. Ian Zagon resulted in the identification of [Met5]-enkephalin as the endogenous ligand for the OGF-OGFr pathway. Subsequently, a new nuclear-associated receptor was identified and termed OGFr. One group in the laboratory has characterized and cloned the OGFr gene in human, mouse and rat. Protein chemistry studies, along with structural biology, determined that the OGFr is a uniquely unstructured nuclear receptor. The mechanism of action was determined to involve inhibition of DNA synthesis with the specific mechanistic pathway involving upregulation of cyclin-dependent inhibitory kinases p16 and p21. OGF action is receptor-mediated, reversible, and not associated with apoptosis/necrosis. OGF is tissue non-specific and has been identified in proliferating cells and tissues derived from all 3 dermal layers.

Currently, the lab’s work is translational, focusing on disease-based pathways that are characterized by a perturbation in the OGF-OGFr axis. Consequences of receptor blockade of the OGF-OGFr axis are being studied with an emphasis on the etiology and treatment of complications (e.g., delayed wound healing, dry eye, impaired bone composition) arising from long-term diabetes (Type 1 or Type 2). These investigations (humans and animal models) focus on treatment options and utilize confocal microscopy, animal surgery, immunohistochemistry and tissue culture.

In another series of studies, the lab is testing the hypothesis that down-regulation of the inhibitory OGF peptide plays a role in multiple sclerosis and other autoimmune diseases. The lab is also currently validating serum biomarkers and cytokine expression profiles that correspond to changes in behavior and MRI imaging that may be related to disease progression and response to therapy. The clinical and animal research is both qualitative and quantitative in design and is supported by NIH, ADA, TSF (PA) and foundations.

  • Opioid Analgesics
  • Intercellular Signaling Peptides and Proteins
  • Naltrexone
  • methionine-enkephalin receptor
  • Growth
  • Opioid Receptors
  • Enkephalins
  • Neoplasms
  • Cell Proliferation
  • Therapeutics
  • Narcotic Antagonists
  • DNA

Recent Publications

2019

Titunick, MB, Lewis, G, Cain, J, Zagon, I & McLaughlin, P 2019, 'Blockade of the OGF-OGFr pathway in diabetic bone' Connective Tissue Research. https://doi.org/10.1080/03008207.2019.1593396
McLaughlin, P, Sassani, J, Titunick, MB & Zagon, I 2019, 'Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes' BMC Ophthalmology, vol. 19, no. 1, 35. https://doi.org/10.1186/s12886-019-1044-y

2018

Zagon, I & McLaughlin, P 2018, 'Intermittent blockade of OGFr and treatment of autoimmune disorders', Experimental Biology and Medicine, vol. 243, no. 17-18, pp. 1323-1330. https://doi.org/10.1177/1535370218817746

2017

Ludwig, MD, Zagon, I & McLaughlin, P 2017, 'Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis', Brain Research Bulletin, vol. 134, pp. 1-9. https://doi.org/10.1016/j.brainresbull.2017.06.015
Stockdale, DP, Titunick, MB, Biegler, JM, Reed, JL, Hartung, AM, Wiemer, DF, McLaughlin, P & Neighbors, J 2017, 'Selective opioid growth factor receptor antagonists based on a stilbene isostere' Bioorganic and Medicinal Chemistry, vol. 25, no. 16, pp. 4464-4474. https://doi.org/10.1016/j.bmc.2017.06.035
McLaughlin, P, Cain, J, Titunick, MB, Sassani, J & Zagon, I 2017, 'Topical Naltrexone is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds', Advances in Wound Care, vol. 6, no. 9, pp. 279-288. https://doi.org/10.1089/wound.2016.0725

2016

Kren, NP, Zagon, I & McLaughlin, P 2016, 'Featured Article: Nuclear export of opioid growth factor receptor is CRM1 dependent', Experimental Biology and Medicine, vol. 241, no. 3, pp. 273-281. https://doi.org/10.1177/1535370215605585
Hammer, LA, Waldner, H, Zagon, I & McLaughlin, P 2016, 'Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis', Experimental Biology and Medicine, vol. 241, no. 1, pp. 71-78. https://doi.org/10.1177/1535370215596384
Liang, D, Sassani, J, McLaughlin, P & Zagon, I 2016, 'Topical Application of Naltrexone to the Ocular Surface of Healthy Volunteers: A Tolerability Study', Journal of Ocular Pharmacology and Therapeutics, vol. 32, no. 2, pp. 127-132. https://doi.org/10.1089/jop.2015.0070

2015

McLaughlin, P & Zagon, I 2015, 'Duration of opioid receptor blockade determines biotherapeutic response' Biochemical Pharmacology, vol. 97, no. 3, pp. 236-246. https://doi.org/10.1016/j.bcp.2015.06.016
McLaughlin, P, McHugh, DP, Magister, MJ & Zagon, I 2015, 'Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis' BMC Immunology, vol. 16, no. 1, 24. https://doi.org/10.1186/s12865-015-0093-0
Hammer, LA, Zagon, I & McLaughlin, P 2015, 'Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: Implications for the treatment of multiple sclerosis' Brain Research Bulletin, vol. 112, pp. 42-51. https://doi.org/10.1016/j.brainresbull.2015.01.009
Turel, AP, Oh, KH, Zagon, I & McLaughlin, P 2015, 'Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability', Journal of Clinical Psychopharmacology, vol. 35, no. 5, pp. 609-611. https://doi.org/10.1097/JCP.0000000000000373
Kren, NP, Zagon, I & McLaughlin, P 2015, 'Mutations in the opioid growth factor receptor in human cancers alter receptor function', International Journal of Molecular Medicine, vol. 36, no. 1, pp. 289-293. https://doi.org/10.3892/ijmm.2015.2221

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)